0001213900-21-046949.txt : 20210908 0001213900-21-046949.hdr.sgml : 20210908 20210908060457 ACCESSION NUMBER: 0001213900-21-046949 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20210907 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20210908 DATE AS OF CHANGE: 20210908 FILER: COMPANY DATA: COMPANY CONFORMED NAME: InMed Pharmaceuticals Inc. CENTRAL INDEX KEY: 0001728328 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: A1 FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39685 FILM NUMBER: 211240595 BUSINESS ADDRESS: STREET 1: SUITE 310, 815 W. HASTINGS STREET CITY: VANCOUVER STATE: A1 ZIP: V6C 1B4 BUSINESS PHONE: (604) 669-7207 MAIL ADDRESS: STREET 1: SUITE 310, 815 W. HASTINGS STREET CITY: VANCOUVER STATE: A1 ZIP: V6C 1B4 8-K 1 ea147035-8k_inmedpharma.htm CURRENT REPORT
0001728328 false A1 CA 0001728328 2021-09-07 2021-09-07 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

 

FORM 8-K

 

 

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): September 7, 2021

 

 

 

INMED PHARMACEUTICALS INC.

(Exact Name of Company as Specified in Charter)

 

 

 

British Columbia   001-39685   98-1428279

(State or Other Jurisdiction

of Incorporation)

  

(Commission File Number)

  

(IRS Employer

Identification No.)

 

InMed Pharmaceuticals Inc.

Suite 310 - 815 W. Hastings Street,

Vancouver, B.C.

Canada

   V6C 1B4
(Address of Principal Executive Offices)   (Zip Code)

 

Company’s telephone number, including area code: (604) 669-7207

 

Not applicable

(Former Name or Former Address, if Changed Since Last Report)

 

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class  

Trading Symbol(s)

   Name of each exchange on which registered
Common Shares, no par value   INM   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

 

Emerging growth company  ☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

 

 

 

 

 

 

Item 7.01 Regulation FD Disclosure.

 

On September 7, 2021, the Company announced that Eric. A. Adams, President and CEO of InMed, will present live at VirtualInvestorConferences.com on September 8, 2021.

 

The information set forth in this Item 7.01, including Exhibit 99.1, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. The information set forth in this Item 7.01, including Exhibit 99.1, shall not be deemed incorporated by reference into any other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

 

Item 9.01. Financial Statements and Exhibits.

 

(d) Exhibits:

 

The following exhibits shall be deemed to be furnished, and not filed:

 

Exhibit No.   Description
     
99.1   News release, dated September 7, 2021
104   Cover Page Interactive Data File (embedded within the Inline XBRL document and included as Exhibit 101)

 

1

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  INMED PHARMACEUTICALS INC.
     
Date: September 7, 2021 By: /s/ Bruce Colwill
    Bruce Colwill
    Chief Financial Officer

 

 

2

 

 

 EX-99.1 2 ea147035ex99-1_inmedpharma.htm NEWS RELEASE, DATED SEPTEMBER 7, 2021

Exhibit 99.1 

 

InMed Pharmaceuticals to Webcast Live at VirtualInvestorConferences.com September 8th

 

InMed Pharmaceuticals invites individual and institutional investors, as well as advisors and analysts, to attend real-time, interactive presentations on VirtualInvestorConferences.com

 

Vancouver, BC - September 7, 2021 /PRNewswire/ -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the manufacturing and development of rare cannabinoids, announced that Eric. A. Adams, President and CEO of InMed, will present live at VirtualInvestorConferences.com on September 8, 2021.

 

DATE: September 8th, 2021

TIME: 1:30 PM EST

LINK: https://bit.ly/3ylJi2m

 

This will be a live, interactive online event where investors are invited to ask the company questions in real-time. If attendees are not able to join the event live on the day of the conference, an archived webcast will also be made available after the event.

 

It is recommended that investors pre-register and run the online system check to expedite participation and receive event updates.

 

Learn more about the event at www.virtualinvestorconferences.com.

 

Recent Company Highlights:

 

●InMed increased the yield of their proprietary IntegraSyn™ rare cannabinoid manufacturing approach to 5 g/L, further improving the overall economics in advance of commercial scale production.
   
●InMed’s rare cannabinoid yield of 5 g/L significantly exceeds currently reported industry yields, further validating the IntegraSyn™ manufacturing approach as a commercially viable solution for large-scale, pharmaceutical-grade GMP production of rare cannabinoids.
   
●InMed announced a non-binding letter of intent to acquire BayMedica, a private company based in Nevada and California that specializes in the manufacture and commercialization of rare cannabinoids.
   
●InMed has filed clinical trial applications in several countries as part of a Phase 2 Clinical Trial to evaluate INM-755 (cannabinol) cream for the treatment of Epidermolysis Bullosa.
   

###

About InMed

 

InMed Pharmaceuticals is a clinical-stage company developing a pipeline of cannabinoid-based pharmaceutical drug candidates, initially focused on the therapeutic benefits of cannabinol (“CBN”) and is developing IntegraSyn™ to produce pharmaceutical-grade cannabinoids. The Company is dedicated to delivering new therapeutic alternatives to patients that may benefit from cannabinoid-based pharmaceutical drugs. For more information, visit www.inmedpharma.com.

 

 

 

About Virtual Investor Conferences®

 

Virtual Investor Conferences (VIC) is the leading proprietary investor conference series that provides an interactive forum for publicly-traded companies to meet and present directly with investors.

A real-time solution for investor engagement, Virtual Investor Conferences is part of OTC Market Group’s suite of investor relations services specifically designed for more efficient Investor Access.  Replicating the look and feel of on-site investor conferences, Virtual Investor Conferences combine leading-edge conferencing and investor communications capabilities with a comprehensive global investor audience network.

 

CONTACTS:

InMed Pharmaceuticals

Colin Clancy

Senior Director

Investor Relations

+1 604 416 0999

cclancy@inmedpharma.com

 

Virtual Investor Conferences

John M. Viglotti

SVP Corporate Services, Investor Access

OTC Markets Group

(212) 220-2221

johnv@otcmarkets.com

 

Cautionary Note Regarding Forward-Looking Information:

 

This news release contains “forward-looking information” and “forward-looking statements” (collectively, “forward-looking information”) within the meaning of applicable securities laws. Forward-looking information is based on management’s current expectations and beliefs and is subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Forward-looking information in this news release includes statements about: presenting present live at the Virtual Investor Conferences on September 8, 2021; delivering new therapeutic alternatives to patients that may benefit from cannabinoid-based pharmaceutical drugs; advancing IntegraSynTM to commercial scale production; IntegraSynTM being a commercially viable solution for large-scale, pharmaceutical-grade GMP production of rare cannabinoids; and developing a pipeline of cannabinoid-based pharmaceutical drug candidates. All forward-looking information herein is qualified in its entirety by this cautionary statement, and InMed disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by law.

 

 

 

 

 EX-101.SCH 3 inm-20210907.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 inm-20210907_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 inm-20210907_pre.xml XBRL PRESENTATION FILE XML 6 ea147035-8k_inmedpharma_htm.xml IDEA: XBRL DOCUMENT 0001728328 2021-09-07 2021-09-07 iso4217:USD shares iso4217:USD shares 0001728328 false A1 CA 8-K 2021-09-07 INMED PHARMACEUTICALS INC. 001-39685 98-1428279 Suite 310 - 815 W. Hastings Street, Vancouver, B.C. V6C 1B4 (604) 669-7207 false false false false Common Shares, no par value INM NASDAQ true false XML 7 R1.htm IDEA: XBRL DOCUMENT v3.21.2
Cover
Sep. 07, 2021
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Sep. 07, 2021
Entity File Number 001-39685
Entity Registrant Name INMED PHARMACEUTICALS INC.
Entity Central Index Key 0001728328
Entity Tax Identification Number 98-1428279
Entity Incorporation, State or Country Code A1
Entity Address, Address Line One Suite 310 - 815 W. Hastings Street,
Entity Address, City or Town Vancouver, B.C.
Entity Address, Country CA
Entity Address, Postal Zip Code V6C 1B4
City Area Code (604)
Local Phone Number 669-7207
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Shares, no par value
Trading Symbol INM
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Elected Not To Use the Extended Transition Period false
EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.2 html 1 96 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://inmedpharma.com/role/Cover Cover Cover 1 false false All Reports Book All Reports ea147035-8k_inmedpharma.htm ea147035ex99-1_inmedpharma.htm inm-20210907.xsd inm-20210907_lab.xml inm-20210907_pre.xml http://xbrl.sec.gov/dei/2021 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "ea147035-8k_inmedpharma.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "ea147035-8k_inmedpharma.htm" ] }, "labelLink": { "local": [ "inm-20210907_lab.xml" ] }, "presentationLink": { "local": [ "inm-20210907_pre.xml" ] }, "schema": { "local": [ "inm-20210907.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd", "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021_doc.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021_ref.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021": 4, "total": 4 }, "keyCustom": 0, "keyStandard": 96, "memberCustom": 0, "memberStandard": 0, "nsprefix": "INM", "nsuri": "http://inmedpharma.com/20210907", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "ea147035-8k_inmedpharma.htm", "contextRef": "From2021-09-07to2021-09-07", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://inmedpharma.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "ea147035-8k_inmedpharma.htm", "contextRef": "From2021-09-07to2021-09-07", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r9", "r11", "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r11" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://inmedpharma.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r10": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r11": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r12": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r13": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r14": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r15": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r16": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r17": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r18": { "Name": "Securities Act", "Number": "Section", "Publisher": "SEC", "Section": "12" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r9": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" } }, "version": "2.1" } ZIP 15 0001213900-21-046949-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001213900-21-046949-xbrl.zip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